Document |
Document Title |
WO/2024/003904A1 |
The present invention is directed to combination therapies using compositions of Curcumin and Qing-Dai or extracts of plants producing thereof, and their clinical applications to the treatment of inflammatory conditions in general and to...
|
WO/2024/002058A1 |
A method for alleviating radiation-induced skin disorder (e.g., radiation dermatitis), comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising salvigenin, and optionally cirsim...
|
WO/2024/006353A1 |
A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and/or blood components from the human plac...
|
WO/2024/003535A2 |
Disclosed are compounds of the formula (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt or N-oxide thereof: (I) wherein R1, R2, R3, R4, R5, n, m, and x are as defined herein. Compounds of the invention may be suit...
|
WO/2024/000088A1 |
Disclosed in the present invention are a pearl-derived whitening polypeptide and a use thereof. The polypeptide is a polypeptide having an amino acid sequence according to any one of SEQ ID NOs. 1-5. The molecular docking result shows th...
|
WO/2024/003911A1 |
The invention concerns methods and pharmaceutical compositions for use in the treatment of psoriasis comprising as an active ingredient piclidenoson (IB-MECA) in an amount suitable for a daily dose administration of about 6 milligrams (mg).
|
WO/2023/205504A9 |
The invention provides the use of kinase inhibitors and derivatives of staurosporine, such as PKC412, to treat patients having epidermis bullosa simplex (BBS), epidermolytic hyperkeratosis, epidermolytic palmoplantar keratoderma, palmopl...
|
WO/2024/005726A1 |
The present invention provides a storage stable clobetasol topical formulation comprising cetostearyl alcohol and glyceryl stearate in a specific weight percent based on the total composition and comprising citric acid as a pH modifier. ...
|
WO/2024/004656A1 |
Provided is a pharmaceutical composition that is a composition for treating an immune-related adverse event (irAE) in a subject who has undergone a cancer immunotherapy, the pharmaceutical composition containing anthracycline.
|
WO/2024/005132A1 |
The present invention provides a novel therapeutic or prophylactic agent for psoriasis. This therapeutic or prophylactic agent for psoriasis comprises a serotonin-4 receptor agonist.
|
WO/2024/006550A1 |
Compositions and methods for treating alopecia, particularly chemotherapy-induced alopecia, using oxidizers or oxidants, pro-oxidant compounds, or activators of P53. Compositions comprising organic peroxides such as, cumene hydroperoxide...
|
WO/2024/005197A1 |
Provided are: a solid dispersion comprising at least one compound selected from the group consisting of a hetero ring derivative represented by general formula [1], a tautomer of the hetero ring derivative, and a pharmaceutically accepta...
|
WO/2024/000914A1 |
A traditional Chinese medicine composition for treating skin diseases, of which the monarch medicine is composed of the following medicines: 10-30 parts of Rehmannia glutinosa and 5-25 parts of Fructus gardenia; the minister medicine is ...
|
WO/2024/006748A1 |
The present invention provides a high-dose oral pharmaceutical composition and high drug loading of isotretinoin with low fill-weight, and smaller size capsules. The present invention further provides processes for preparing the disclose...
|
WO/2023/247838A1 |
The present invention relates to a cosmetic or dermatological composition comprising at least one substituted or unsubstituted polylysine dendrimer, at least one vitamin and at least one cosmetically and/or dermatologically acceptable ca...
|
WO/2023/249046A1 |
[Problem] To provide a composition (a cosmetic, etc.) for maintaining the structure of hyaluronic acid in human skin and the like, and/or a material (an agent) to be used therein, etc. [Solution] An agent for maintaining the structure of...
|
WO/2023/246135A1 |
The present disclosure relates to a peptide, a peptide-modified SIS membrane, a method for preparing same, and use thereof. Specifically, the present disclosure relates to an oligopeptide, a chimeric peptide containing the oligopeptide, ...
|
WO/2023/248845A1 |
The present invention provides: a novel PTX3 expression control agent that uses miRNA from fine particles to control PTX3 expression, the PTX3 expression control agent including fine particles that include miRNA that targets a gene relat...
|
WO/2023/249458A1 |
The present invention relates to: a composition comprising a CPNE7 protein or a CPNE7 protein-derived functional peptide (selcopintide) for removing reactive oxygen species in cells; a polynucleotide encoding the peptide; an expression v...
|
WO/2023/246827A1 |
The present invention relates to the technical field of biological medicines, and particularly, to a micromolecular drug-oligonucleotide conjugate and use thereof. The present invention solves the problems of poor water solubility and di...
|
WO/2023/248196A1 |
The present application relates for a peptide-ionic liquid conjugate for the prevention and/or treatment of skin disorders. The peptide- ionic liquid conjugate comprises a cosmeceutical peptide comprising up to 10 amino acids and at leas...
|
WO/2023/249449A1 |
The present application relates to a pharmaceutical composition for wound treatment . Specifically, the present application concerns a composition including a wound-coating material and chemokine-adsorbing particles to absorb inflammator...
|
WO/2023/245291A1 |
Therapeutic compositions, kits, and methods and uses thereof are provided. The compositions comprise zinc oxide, hydrocortisone, and/or clotrimazole.
|
WO/2023/247870A1 |
The present invention relates to a cosmetic or dermatological composition comprising at least one substituted or unsubstituted polylysine dendrimer, at least one vitamin and at least one cosmetically and/or dermatologically acceptable ca...
|
WO/2023/250181A1 |
Provided is a compound having the structure of Formula (1) or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof, wherein A, B, Ri, R2, R3, R4, R5, R6, R7, m, 11, p, and y are as defined herein, for use in methods fo...
|
WO/2023/249017A1 |
The present invention uses a lactic acid bacteria fermentation product of sap of a plant of the genus Betula as an active ingredient of an anti-aging agent, hair growth agent, and anti-androgen agent. An anti-aging agent, hair growth age...
|
WO/2023/245256A1 |
The present disclosure relates generally to antimicrobial gels. In particular, the present disclosure relates to an antimicrobial gel comprising a eutectic solvent and a gelling agent which can be used as a drug delivery vehicle for anti...
|
WO/2023/250513A1 |
Provided are 13-membered macrolides that can be used to treat proliferative diseases such as cancer as well as genetic diseases that are associated with a premature termination codon mutation or other nonsense mutations. The compounds ca...
|
WO/2023/247796A1 |
The present disclosure relates to a skin care composition comprising boswellic acids and vitamin B12 or derivatives thereof. The compositions can be advantageously used in a method of treatment of dermatological conditions, disorders or ...
|
WO/2023/242007A1 |
The present invention relates to the use of selected UV filters selected from the group consisting of octocrylene, ethyl hexyltriazone and butyl methoxydibenzoylmethane for the concomitant protection of skin bacteria of the genus Lactoba...
|
WO/2023/244132A1 |
The present invention refers to a potent inhibitor of the transforming growth factor beta (TGFβ) receptor I (TβRI), galunisertib (LY2157299), for use in the treatment of androgenic alopecia (AGA), acting against TGFβ repressive signal...
|
WO/2023/245016A1 |
The present disclosure relates to cyclic oligopeptides that bind to interleukin-13 (IL-13) which are useful therapeutically in methods of treating or preventing IL-13-associated skin disorders or conditions. The present disclosure also p...
|
WO/2023/240379A1 |
Provided in the present invention are an imidazolinone derivative and the use thereof. The imidazolinone derivative is a compound having a structure as shown in the following formula (I) or (II) or a pharmaceutically acceptable salt, ste...
|
WO/2023/243935A1 |
The present invention relates to a pharmaceutical composition for preventing or treating acne. More specifically, the present invention comprises antibiotics, bentonite, kaolin clay, corn starch, agar, titanium dioxide (TiO2), and talc, ...
|
WO/2023/243924A1 |
The present invention relates to a novel Micrococcus terreus strain, a disrupted solution thereof, a culture medium, an extract of the culture medium, and a use thereof for improving skin condition. The strain has a skin condition-improv...
|
WO/2023/242605A1 |
The invention relates to algal extracellular vesicles (EVs) for use in therapy and in restoring or maintaining health of a subject. In particular the invention relates to uses of algal EVs in therapy, wherein the EVs themselves have favo...
|
WO/2023/243689A1 |
The present invention provides: a sepsis and/or septic shock therapeutic agent containing, as an active ingredient, a compound that suppresses phosphorylation of threonine at position 749 of human STAT1; a method for screening a candidat...
|
WO/2023/242338A1 |
The present invention relates to a method for producing acylated derivate of polyphenols comprising α-glucosylation of the phloretin with a sucrose phosphorylase mutant from T. thermosaccharolyticum and acylation with the lipase from Th...
|
WO/2023/243166A1 |
The present invention addresses the problem of effectively promoting granulation in a dermal defect or a subcutaneous tissue defect caused by a severe burn. To solve this problem, provided is a cell to be used for treating a burn, said c...
|
WO/2023/242008A1 |
The present invention relates to the use of selected UV filters selected from the group consisting of octocrylene, ethyl hexyltriazone and butyl methoxydibenzoylmethane for the protection of skin bacteria of the genus Lactobacillus such ...
|
WO/2023/241716A1 |
Provided is use of a protein synthesis inhibitor in promoting regeneration and repair capacity of mammal tissues or complex structures or organs. The protein synthesis inhibitor is a small molecule compound, from any of cycloheximide or ...
|
WO/2023/241119A1 |
Disclosed is use of chaetocin in anti-aging. The present invention adopts an aging cell model and an aging mouse model to screen and obtain a drug, chaetocin, which has the effect of anti-aging. By means of cell and mouse experiment veri...
|
WO/2023/244738A1 |
Methods for treating a disease, condition, or disorder associated with impaired muscle regeneration, including a muscular dystrophy, such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), or limb-girdle muscular d...
|
WO/2023/242006A1 |
The present invention relates to the use of selected UV filters selected from the group consisting of octocrylene, ethylhexyl salicylate and butyl methoxydibenzoylmethane to reduce the abundance of C. acnes strains in a skin microbiome a...
|
WO/2023/244666A1 |
The present disclosure relates to skincare compositions that include sunflower sprout extract for treating skin conditions. More specifically, novel aspects are directed to a metabolomics guided, bioprocess engineered sunflower sprout ex...
|
WO/2023/242339A1 |
The subject matter of the present invention relates to a composition having hepatoprotective effect and comprising petasin and isopetasin, its use as dietary food item, food supplement, medicinal product, pharmaceutical composition or dr...
|
WO/2023/243447A1 |
The purpose is to clarify the internal structures of the skin related to sagging and to provide a novel cosmetic method for preventing and improving sagging. Firmness of the skin was discovered to be due to circular collagen in the dermi...
|
WO/2023/241717A1 |
Provided is use of a substance capable of up-regulating ISG gene expression in preparing a drug or reagent for promoting the regeneration and repair capacity of tissues or complex structures or organs of mammals. The substance for up-reg...
|
WO/2023/241715A1 |
Provided is use of a retinoic acid receptor activator or a composition containing the retinoic acid receptor activator in preparing a drug or reagent for promoting the regeneration and repair capacity of tissues or complex structures or ...
|
WO/2023/243835A1 |
The present invention relates to bacteriophage having the ability to kill Cutibacterium acnes and, more specifically, to bacteriophage CAP-1 having the ability to kill Cutibacterium acnes, which proliferates on the skin and induces infla...
|